安罗替尼联合替吉奥及奈达铂方案治疗复发食管鳞癌近期疗效观察

Observation on the short-term effect of anlotinib combined with tegafur gimeracil and oteracil potassium and nedaplatin on treatment of recurrent esophageal squamous cell carcinoma

目的观察安罗替尼联合替吉奥及奈达铂方案治疗复发食管鳞癌的近期疗效及不良反应。方法选择该院2018-10~2019-10间收治的一线放化疗后复发食管鳞癌患者36例,随机分为安罗替尼联合替吉奥、奈达铂治疗组(观察组)和替吉奥、奈达铂治疗组(对照组)各18例,观察两组治疗后的疗效及不良反应。结果观察组治疗客观缓解率为16.7%,疾病控制率为61.1%,疾病控制率与对照组比较差异有统计学意义(P<0.05)。观察组中位无进展生存期为3.7个月,对照组为2.3个月,两组比较差异有统计学意义(P<0.05)。观察组高血压发生率高于对照组,差异有统计学意义(P<0.05)。结论安罗替尼联合替吉奥、奈达铂是复发食管鳞癌有效的治疗方法,不良反应小,患者易于耐受。

Objective To observe the short-term effect and adverse reactions of anlotinib combined with tegafur gimeracil and oteracil potassium(S1)and nedaplatin on treatment of recurrent esophageal squamous cell carcinoma.Methods From October 2018 to October 2019,36 patients with recurrent esophageal squamous cell carcinoma after first-line radiotherapy and chemotherapy were selected and randomly divided into the observation group(treated with anlotinib+S1+nedaplatin)and the control group(treated with S1+nedaplatin),with 18 cases in each group.The curative effect and adverse reactions after treatment were observed in the two groups.Results The objective response rate(ORR)and the disease control rate(DCR)of the observation group were 16.7%and 61.1%respectively,and there was significant difference in the DCR between the observation group and the control group(P<0.05).The median progression-free survival(PFS)was 3.7 months in the observation group and 2.3 months in the control group,and there was significant difference between the two groups(P<0.05).The incidence of hypertension in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Anlotinib plus S1 and nedaplatin is effective for the treatment of recurrent esophageal squamous cell carcinoma,and has few adverse reactions and the patients are tolerable.